MK-1602

DRUG2 trials

Sponsors

Allergan

Conditions

Migraine

Phase 2

A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)

CompletedNCT01613248

AllerganMigraine

Start: 2012-07-01End: 2012-12-01Updated: 2019-01-08

A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)

CompletedNCT01657370

AllerganMigraine

Start: 2012-08-31End: 2012-12-31Updated: 2016-12-09

Related Papers

Efficacy of ubrogepant and atogepant in males and females with migraine: A secondary analysis of randomized clinical trials.

2025-02-011 citations